³Ä¡¼º °£Áú Ä¡·á´Â °³ÀÎÀÇ µ¶Æ¯ÇÑ ÀÓ»óÀû, ºÐÀÚÀû, »ýȰ ¹æ½Ä µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¿© ¾Ï, À¯Àü¼º Áúȯ, ±âŸ º¹ÀâÇÑ ÁúȯÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ» Áö¿øÇÕ´Ï´Ù. ³Ä¡¼º °£Áú Ä¡·á´Â ÀüÅëÀûÀÎ ÀÏ·üÀûÀÎ Á¢±Ù ¹æ½Ä¿¡¼ ¹þ¾î³ª °³ÀÎ ¸ÂÃãÇü ¹× Ç¥Àû Ä¡·á Àü·«À¸·ÎÀÇ Çõ½ÅÀûÀÎ ÀüȯÀ» »ó¡ÇÕ´Ï´Ù.
À¯ÀüüÇÐ, ºÐÀÚ Áø´Ü, µ¥ÀÌÅÍ ºÐ¼® ºÐ¾ßÀÇ Áøº¸¸¦ Ȱ¿ëÇØ ³Ä¡¼º °£Áú Ä¡·á´Â °³ÀÎÀÇ À¯ÀüÀû, ȯ°æÀû, »ýȰ ¹æ½Ä ¿äÀÎÀ» ±â¹ÝÀ¸·Î ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀº Ä¡·á È¿°ú¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ºÒÇÊ¿äÇÑ ½Ãµµ¿Í ¿À·ù¸¦ ÁÙ¿© ȯÀÚ °á°ú °³¼±°ú ÀÇ·á ºñ¿ë Àý°¨À¸·Î À̾îÁý´Ï´Ù. ÀÌ ºÐ¾ß°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ´ë±Ô¸ð Àα¸ ±â¹Ý ¿¬±¸¿Í ÃÖ÷´Ü ±â¼úÀº ´õ Á¤È®ÇÑ Áúº´ ¿¹Ãø, Á¶±â Áø´Ü, ÃÖÀûÈµÈ Ä¡·á °³ÀÔÀ» À§ÇÑ ±æÀ» ¿¾î°¡°í ÀÖ½À´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è | |
---|---|
¿¹Ãø ±â°£ | 2025-2035³â |
Æò°¡(2025³â) | 49¾ï 240¸¸ ´Þ·¯ |
¿¹Ãø(2035³â) | 94¾ï 7,260¸¸ ´Þ·¯ |
CAGR | 6.71% |
½ÃÀå ¼Ò°³
¼¼°èÀÇ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀå ±Ô¸ð´Â ´ëÆøÀûÀÎ ¼ºÀåÀÌ ¿¹»óµÇ¸ç, 2035³â¿¡´Â 94¾ï 7,260¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº °£ÁúÀÇ À¯º´·ü Áõ°¡¿Í ÀüÅëÀûÀÎ Ç×°æ·ÃÁ¦ÀÇ ÇѰè·Î ÀÎÇØ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀüÅëÀûÀÎ ¾à¹°Àº ȯÀÚÀÇ ¾à 30-40%¿¡¼ ¹ßÀÛÀ» ÅëÁ¦ÇÏÁö ¸øÇϱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ Áß¿äÇÑ ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä´Â ½ÃÀå ±¸Á¶¸¦ º¯È½Ã۰í ÀÖÀ¸¸ç, ½Å°æ ÀÚ±Ø Ä¡·á¹ý(VNS, RNS, DBS µî), ¼ö¼úÀû °³ÀÔ, ´ë¸¶ÃÊ ÃßÃâ¹°(ijªºñµð¿Ã) ¹× Â÷¼¼´ë Ç×°æ·ÃÁ¦¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ºÀå¼¼´Â ½ÅÈï ½ÃÀå¿¡¼ ÀÎ½Ä Çâ»ó, Áø´Ü ´É·Â °È, ÀÇ·á Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ°í ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ³ôÀº Ä¡·á ºñ¿ë, º¹ÀâÇÑ ±ÔÁ¦ ¿ä°Ç, Àü¹® ÀÇ·á ¼ºñ½º Á¢±Ù¼º ºÒ±ÕÇü µî Àå¾Ö¹°ÀÌ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß°¡ °³ÀÎÈ, ±â±â ÅëÇÕ, Á¤¹Ð Ç¥ÀûÈ ¼Ö·ç¼ÇÀ¸·Î ÁøÈÇÔ¿¡ µû¶ó ³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀº ±ä±ÞÇÑ ÀÓ»óÀû Çʿ伺°ú ÁøÈÇÏ´Â »ó¾÷Àû ÀáÀç·ÂÀÇ ÃÖÀü¼±¿¡ ¼ ÀÖ½À´Ï´Ù.
³Ä¡¼º °£Áú(¾à¹° ÀúÇ×¼º °£Áú, DRE)Àº ¸ðµç °£Áú ȯÀÚÀÇ ¾à 30%¸¦ Â÷ÁöÇϸç, µÎ °¡Áö ÀÌ»óÀÇ Ç×°æ·ÃÁ¦(ASM)¿¡ ÃæºÐÈ÷ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚ¸¦ ÀǹÌÇÕ´Ï´Ù. ÀÌ ÁúȯÀº ³ôÀº ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ ¹Ý¿µÇϸç, Á¦¾à ¹× ÀÇ·á±â±â Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ³Ä¡¼º °£ÁúÀº ¼¼°èÀÇ °£Áú ȯÀÚÀÇ ¾à 30%¸¦ Â÷ÁöÇϸç, ÀÌ´Â Áß¿äÇÑ ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÀÌ È¯ÀÚ±ºÀº µÎ °¡Áö ÀÌ»óÀÇ Ç×°æ·ÃÁ¦(ASM)¸¦ ½ÃµµÇصµ ¹ßÀÛ ÅëÁ¦¸¦ ´Þ¼ºÇÏÁö ¸øÇØ Çõ½ÅÀûÀÎ Ä¡·á¹ý ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. °æÀï ȯ°æÀº Á¦¾à, ÀÇ·á±â±â, ½ÅÈï À¯ÀüÀÚ Ä¡·á ºÐ¾ß¸¦ ¾Æ¿ì¸£¸ç ´Ù¾çÇÏ°í ºü¸£°Ô º¯ÈÇϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀÎ ASMÀÎ UCB PharmaÀÇ ºê¸®¹Ù¶ó¼¼Å½°ú SK Life ScienceÀÇ ¼¼³ë¹Ù¸¶Å×´Â È¿´É°ú ³»¾à¼º °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃç °è¼Ó ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼¼³ë¹Ù¸¶Å×ÀÇ ÀÓ»ó ½ÃÇè¿¡¼ ´«¿¡ ¶ç´Â ¹ßÀÛ ÀÚÀ¯À² °á°ú°¡ À̸¦ ÀÔÁõÇÕ´Ï´Ù. ÇÑÆí, LivaNovaÀÇ ºÎ±³°¨½Å°æ ÀÚ±Ø ÀåÄ¡¿Í NeuroPaceÀÇ ¹ÝÀÀÇü ½Å°æ ÀÚ±Ø ½Ã½ºÅÛ°ú °°Àº ½Å°æ Á¶Àý ÀåÄ¡´Â ¼ö¼úÀÌ ¾î·Á¿î ±¹¼Ò¼º °£Áú ȯÀÚ¸¦ ´ë»óÀ¸·Î ½Å°æ ȸ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ´ëü Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù.
¶ÇÇÑ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á´Â µå¶óº£ ÁõÈıº°ú °°Àº Èñ±Í À¯Àü¼º °£Áú¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ÀáÀç·ÂÀ» º¸¿©ÁÖ¸ç, Á¤¹Ð ÀÇÇÐÀ¸·ÎÀÇ ÀüȯÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ±ÔÁ¦ Àμ¾Æ¼ºê¿Í ÁöºÒÀÚ ¼ö¿ëµµ Áõ°¡¿¡ ÈûÀÔ°í ÀÖÀ¸¸ç, ƯÈ÷ ½ÇÁ¦ ¼¼°è µ¥ÀÌÅͰ¡ ÀÌ·¯ÇÑ °í±Þ Ä¡·á¹ýÀÇ Àå±âÀû ÇýÅÃÀ» °ËÁõÇÔ¿¡ µû¶ó ´õ¿í °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ÀüüÀûÀ¸·Î ³Ä¡¼º °£Áú Ä¡·á ȯ°æÀº ¾î·Á¿î ÁöÇüÀ» Ž»öÇÏ´Â ´Ù¸ð´Þ ±³Åë ½Ã½ºÅÛ°ú À¯»çÇÕ´Ï´Ù. ÀüÅëÀû ¾à¹°Àº ±¤¹üÀ§ÇÑ È¯ÀÚ±º¿¡ Àû¿ëµÇÁö¸¸ È¿´ÉÀÌ Á¦ÇÑÀûÀ̸ç, ½Å°æÁ¶ÀýÀº ´õ Á¤¹ÐÇÑ ÅëÁ¦¸¦ Á¦°øÇÏÁö¸¸ ºñ¿ëÀÌ ³ô°í, ½ÅÈï À¯ÀüÀÚ Ä¡·á´Â ¼±ÅÃÀû ȯÀÚ±ºÀ» ´ë»óÀ¸·Î ÇÑ Ç¥ÀûÈµÇ°í ¿ÏÄ¡ °¡´ÉÇÑ Ä¡·á °æ·Î¸¦ Á¦½ÃÇÕ´Ï´Ù.
»ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ
³Ä¡¼º °£Áú Ä¡·á´Â ȯÀÚ °á°ú¸¦ Å©°Ô °³¼±ÇÏ´Â ¸ÂÃãÇü Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÇ·á »ê¾÷À» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Á¾¾çÇÐ ºÐ¾ß¿¡¼ À¯ÀüÀû ÇÁ·ÎÆÄÀϸµÀÇ È°¿ëÀº À¯¹æ¾Ï Ä¡·á¸¦ À§ÇØ HER2 ¾ç¼º Á¾¾ç ȯÀÚ¸¦ ´ë»óÀ¸·Î ¼³°èµÈ Herceptin°ú °°Àº Ç¥Àû Ä¡·áÁ¦ÀÇ °³¹ß·Î À̾îÁ³½À´Ï´Ù. °³Àκ° ȯÀÚ Ä¡·á °³¼± ¿Ü¿¡µµ, ³Ä¡¼º °£Áú Ä¡·á´Â ÀÇ·á »ýŰè Àü¹Ý, ƯÈ÷ ½Å¾à °³¹ß°ú ÀÓ»ó ½ÃÇè ºÐ¾ß¿¡¼ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷Àº À¯ÀüüÇÐÀ» Ȱ¿ëÇØ »õ·Î¿î ¾à¹° Ç¥ÀûÀ» ¹ß°ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹éÇ÷º´ Ä¡·áÁ¦ÀÎ Çõ½ÅÀû ¾à¹° Kymriah´Â Áúº´ ƯÀÌÀû À¯ÀüÀû Ç¥ÁöÀÚ¸¦ ½Äº°ÇØ °³¹ßµÈ CAR-T Ä¡·áÁ¦ÀÔ´Ï´Ù. ÀÓ»ó ½ÃÇèµµ ´õ¿í Ÿ°ÙÆÃȵǰí ÀÖÀ¸¸ç, ³ë¹ÙƼ½º¿Í ÈÀÌÀÚ °°Àº ±â¾÷Àº À¯Àüü µ¥ÀÌÅ͸¦ Ȱ¿ëÇØ ȯÀÚ Áý´ÜÀ» ºÐ·ùÇϰí ÀÓ»ó ½ÃÇè È¿À²¼ºÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³Ä¡¼º °£Áú Ä¡·á°¡ Àα¸ °Ç° °ü¸®¿¡ ÅëÇյǴ »ç·Ê·Î Geisinger Health SystemÀÇ MyCode Community Health Initiative°¡ ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î±×·¥Àº ȯÀÚ¿¡°Ô À¯Àüü ½ÃÄö½ÌÀ» Á¦°øÇØ ¿¹¹æ ÀÇ·á¿Í Á¶±â Áúȯ ¹ß°ßÀ» °³¼±ÇÕ´Ï´Ù. ³Ä¡¼º °£Áú Ä¡·áÀÇ ÀÌ·¯ÇÑ È®´ë Àû¿ëÀº °³Àκ° Ä¡·á °á°ú¸¦ °³¼±ÇßÀ» »Ó¸¸ ¾Æ´Ï¶ó ÀÇ·á Á¦°ø ½Ã½ºÅÛ ÃÖÀûÈ, ºñ¿ë Àý°¨, ½Å±Ô Ä¡·á¹ý °³¹ß °¡¼ÓÈ¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼¼ºÐÈ
¼¼ºÐÈ 1 : Ä¡·á À¯Çüº°
1¼¼´ë ÀǾàǰ
2¼¼´ë ÀǾàǰ
½Å¾à ¹× ½Å±Ô ÀǾàǰ
º¹ÇÕ ¾à¹°
ÀýÁ¦ ¼ö¼ú ÀåÄ¡
·¹ÀÌÀú °£Áú ¿ Ä¡·á(LiTT)
½ºÅ×·¹¿ÀŸÇÈ EEG
½ÉºÎ ³ú ÀÚ±Ø(DBS)
ºÎ±³°¨ ½Å°æ ÀÚ±Ø(VNS)
Àü±Ø/¸®µå
¹èÅ͸® ¹× ÆÞ½º ¹ß»ý±â
¼ö¼ú µµ±¸ ¹× ŰƮ
¿ÜºÎ ¾×¼¼¼¸®
¾à¹° Ä¡·á´Â ³Ä¡¼º °£Áú °ü¸®ÀÇ Ã¹ ¹øÂ° Á¢±Ù¹ýÀ¸·Î Ç×°£Áú ¾à¹°(AED)ÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ¸·Î ÀÎÇØ ÁÖ¿ä ¼¼ºÐÈ ½ÃÀåÀ¸·Î À¯ÁöµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº 2024³â ½ÃÀå Á¡À¯À² 90.60%¸¦ ±â·ÏÇßÀ¸¸ç, 2025³âºÎÅÍ 2035³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 6.87%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾à¹° Á¦ÇüÀÇ Áö¼ÓÀûÀÎ °³¼±°ú ÇÔ²² È¿´ÉÀÌ Çâ»óµÇ°í ºÎÀÛ¿ëÀÌ ÀûÀº Â÷¼¼´ë AEDÀÇ Á¢±Ù¼º Áõ°¡°¡ 2035³â±îÁö ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼ºÐÈ 2 : ȯÀÚ À¯Çüº°
ȯÀÚ À¯Çüº°·Î º¸¸é, ¼¼°èÀÇ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀº ¼Ò¾Æ ºÎ¹®ÀÌ °ßÀÎÇØ 2024³âÀÇ Á¡À¯À²Àº 59.6%¿´½À´Ï´Ù. ¼Ò¾Æ Àα¸´Â ¼ºÀο¡ ºñÇØ °£Áú À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀå¿¡¼ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Áø´ÜÀ² Çâ»ó, °í·É Àα¸ Áõ°¡, ¼ºÀÎ ±×·ìÀÇ ÀÇ·á ÀÎ½Ä Çâ»ó µîÀÌ È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¼¼ºÐÈ 3 : ¹ßÀÛ À¯Çüº°
¹ßÀÛ À¯Çüº°·Î º¸¸é, ¼¼°èÀÇ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀº ±¹¼Ò¼º °£ÁúÀÌ °ßÀÎÇØ 2024³âÀÇ Á¡À¯À²Àº 61.4%¿´½À´Ï´Ù. ±¹¼Ò¼º °£ÁúÀº ³Ä¡¼º °£Áú »ç·ÊÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇϱ⠶§¹®¿¡ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ÁúȯÀÇ º¹ÀâÇÏ°í º¯µ¿¼ºÀÌ Å« Áõ»óÀº Ç¥ÁØ Ä¡·á¹ý¿¡ ÀúÇ×¼ºÀ» º¸À̱⠶§¹®¿¡ »õ·Î¿î ¾à¹° ¿É¼Ç°ú ½Å°æ Á¶Àý ±â¼ú µî °í±Þ Ä¡·á Á¢±Ù¹ýÀÇ Çʿ伺À» ³ôÀ̰í ÀÖ½À´Ï´Ù.
¼¼ºÐÈ 4 : À¯Åë ä³Îº°
À¯Åë ä³Îº°·Î´Â 2024³â ±âÁØ º´¿ø ¾à±¹ ºÎ¹®ÀÌ 45.7%ÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¸ç ±Û·Î¹ú ³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. º´¿ø ¾à±¹Àº Àü¹® ÀǾàǰ Á¢±Ù¼º°ú °í±Þ Ä¡·á ÀÎÇÁ¶ó¸¦ °®Ãß°í ÀÖ¾î À¯Åë ä³Î¿¡¼ ¿ìÀ§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³Ä¡¼º °£ÁúÀÇ ÁßÁõ »ç·Ê¿¡¼ ÀÔ¿ø Ä¡·á ¼±È£¿Í º´¿ø ±â¹Ý Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Áõ°¡µµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÕ´Ï´Ù.
¼¼ºÐÈ 5 : Áö¿ªº°
ºÏ¹Ì Áö¿ªÀÇ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ³ôÀº Áúº´ ºÎ´ã, ¼±ÁøÈµÈ ÀÇ·á ÀÎÇÁ¶ó, Çõ½Å¿¡ ´ëÇÑ °ÇÑ ÁýÁßÀ¸·Î ÀÎÇØ »ó´çÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ±Ô¸ð´Â ÇâÈÄ 5³â°£ ¿¬±¸ °³¹ß ÅõÀÚ Áõ°¡, ȯÀÚ ÀÎ½Ä Çâ»ó, Áø´Ü ´É·Â °³¼±À¸·Î ÀÎÇØ ´«¿¡ ¶ç´Â ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â SK Life ScienceÀÇ Cenobamate°¡ Ä¡·á ÀúÇ×¼º ¹ßÀÛ¿¡ ´ëÇÑ È¿°ú¸¦ ÀÔÁõÇϸç FDAÀÇ ÃÖ±Ù ½ÂÀÎÀ» ¹ÞÀº Á¡, Xenon PharmaceuticalsÀÇ XEN1101 µî À¯¸ÁÇÑ Èĺ¸ ¾à¹°ÀÇ ÈÄ±â ´Ü°è °³¹ßÀÌ ÁøÇà ÁßÀ̶ó´Â Á¡ÀÌ ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº È¿´ÉÀ» Çâ»ó½ÃŰ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇϱâ À§ÇØ »õ·Î¿î ÀÛ¿ë ¸ÞÄ¿´ÏÁò°ú ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀ» Àû±ØÀûÀ¸·Î ޱ¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥ È®´ë ¹× °ø°ø-¹Î°£ ¿¬±¸ Çù·Â°ú °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê°¡ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í Çõ½ÅÀ» °¡¼ÓÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ
¼ö¿ä - ÃËÁø¿äÀÎ, µµÀü, ±âȸ
½ÃÀå ¼ö¿ä ÃËÁø¿äÀÎ :
¾à¹° ÀúÇ×¼º °£ÁúÀÇ Áõ°¡¿Í »õ·Î¿î Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÇ Áö¼ÓÀûÀÎ È®Àå : ¾à¹° ÀúÇ×¼º °£ÁúÀº ±¹Á¦ °£Áú ¿¬¸Í(ILAE)¿¡ ÀÇÇØ ÀûÀýÈ÷ ¼±ÅÃµÇ°í ³»¾à¼ºÀÌ ÀÖ´Â µÎ °¡Áö ÀÌ»óÀÇ Ç×°£Áú ¾à¹°(AED)À» ÃæºÐÇÑ ±â°£ µ¿¾È Åõ¿©ÇÑ ÈÄ ¹ßÀÛÀÌ Áö¼ÓµÇÁö ¾Ê´Â °æ¿ì·Î Á¤Àǵ˴ϴÙ. ÀÌ ÇüÅÂÀÇ °£ÁúÀ» ¾Î´Â ȯÀÚµéÀº °Ç° ÇÕº´Áõ À§Çè Áõ°¡, ºÎ»ó ¶Ç´Â °©ÀÛ½º·¯¿î »ç¸Á(SUDEP) À§Çè Áõ°¡, »îÀÇ ÁúÀÌ Å©°Ô ÀúÇϵǴ ¹®Á¦¸¦ °Þ½À´Ï´Ù. ÀÌ °£ÁúÀÇ À¯º´·ü Áõ°¡·Î ÀÇ·á ½Ã½ºÅÛÀÇ ºÎ´ãÀÌ ´õ¿í °¡Áߵǰí ÀÖ½À´Ï´Ù.
UChicago Medicine¿¡ µû¸£¸é ¼¼°èÀÇÀûÀ¸·Î ¾à 6,500¸¸ ¸íÀÌ °£Áú·Î °íÅë¹Þ°í ÀÖÀ¸¸ç, ÀÌ Áß 30-40%(¾à 2,000-2,600¸¸ ¸í)´Â ¾à¹° ÀúÇ×¼º ¶Ç´Â ÀÇÇÐÀû ³Ä¡¼º °£ÁúÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ´Â µÎ °¡Áö ÀÌ»óÀÇ ÀûÀýÇÑ Ç×°£Áú ¾à¹°À» Åõ¿©¹Þ¾ÒÀ½¿¡µµ ºÒ±¸Çϰí Áö¼ÓÀû ¹ßÀÛ ÅëÁ¦¸¦ ´Þ¼ºÇÏÁö ¸øÇÑ °æ¿ì¸¦ ÀǹÌÇÕ´Ï´Ù. ¹Ì±¹ alone¿¡´Â ¾à 200¸¸ ¸íÀÇ ¾à¹° ÀúÇ×¼º °£Áú ȯÀÚ°¡ ÀÖÀ¸¸ç, Àεµ¿¡¼´Â °£Áú ȯÀÚ°¡ 1000¸¸-1200¸¸ ¸íÀ¸·Î ÃßÁ¤µÇ¸ç ÀÌ Áß 30-40%(300¸¸-400¸¸ ¸í)°¡ ¾à¹° ÀúÇ×¼º °£Áú·Î ÃßÁ¤µÇ¾î ¼¼°èÀÇÀûÀ¸·Î »ó´çÇϰí È®´ëµÇ´Â Ä¡·á °ÝÂ÷¸¦ °Á¶Çϰí ÀÖ½À´Ï´Ù.
¾ÆÇÁ¸®Ä«¿¡¼ ¾à¹° ÀúÇ×¼º °£Áú·Î Áø´Ü¹Þ´Â ȯÀÚÀÇ Áõ°¡ Ãß¼¼´Â Áö¿ª ¹× ±Û·Î¹ú ¾à¹° ÀúÇ×¼º °£Áú Ä¡·á ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ºÎ»óÇß½À´Ï´Ù. 2024³â ¹ßÇ¥µÈ ¡°¾ÆÇÁ¸®Ä«¿¡¼ÀÇ ¾à¹° ÀúÇ×¼º °£Áú ¼ö¼ú : ¹ßÀÛ ÀÚÀ¯µµ °á°ú °ËÅ䡱´Â ¾ÆÇÁ¸®Ä« Àü¿ªÀÇ °£Áú ¼ö¼ú ÇÁ·Î±×·¥À» ü°èÀûÀ¸·Î °ËÅäÇß½À´Ï´Ù. 8°³ÀÇ ¿¬±¸¸¦ ºÐ¼®ÇÑ °á°ú, 7°³ÀÇ µ¶Æ¯ÇÑ È¯ÀÚ Áý´Ü¿¡¼ ¼ö¼ú ÈÄ 1³â À̳»¿¡ 60-100%ÀÇ È¯ÀÚ°¡ ¹ßÀÛ ÀÚÀ¯¸¦ ´Þ¼ºÇßÀ¸¸ç, »îÀÇ Áú °³¼±°ú ¿ì¿ïÁõ ½É°¢µµ °¨¼Òµµ °üÂûµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °á°ú´Â °í¼Òµæ Áö¿ª¿¡¼ º¸°íµÈ °á°ú¿Í À¯»çÇϸç, ¾ÆÇÁ¸®Ä«¿¡¼ ¾à¹° ÀúÇ×¼º °£Áú ¼ö¼ú ÇÁ·Î±×·¥ÀÇ ¼³¸³ °¡´É¼º°ú È¿°ú¼ºÀ» ÀÔÁõÇÕ´Ï´Ù. ¾ÆÇÁ¸®Ä«¿¡¼ ¾à¹° Ä¡·á¿¡ ÀúÇ×¼º °£Áú ȯÀÚ°¡ ¹Þ´Â ´Ù¾çÇÑ ¼ö¼ú ÀýÂ÷ÀÇ È¯ÀÚ ¼ö¸¦ ±×·¡ÇÈÀ¸·Î ³ªÅ¸³½ °ÍÀÔ´Ï´Ù.
½ÃÀåÀÇ °úÁ¦
ȯÀÚ Á¢±Ù¿¡ ´ëÇÑ ÀçÁ¤Àû Á¦¾à : ȯÀÚ Á¢±Ù¿¡ ´ëÇÑ ÀçÁ¤Àû Á¦¾àÀº ³Ä¡¼º °£Áú Ä¡·á ½ÃÀå¿¡°Ô Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù. ƯÈ÷ ³Ä¡¼º °£Áú ȯÀÚÀÇ ¸¹Àº ¼ö°¡ »õ·Î¿î ¾à¹°, °í±Þ ¼ö¼ú ¿É¼Ç, ¶Ç´Â ºÎ±³°¨ ½Å°æ ÀÚ±Ø(VNS) ¶Ç´Â RNS¿Í °°Àº ±â±â µî ´Ù¾çÇÑ Ä¡·á¹ýÀÇ Á¶ÇÕÀ» ÇÊ¿ä·Î Çϱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ºñ¿ëÀÌ ¸Å¿ì ³ôÀ» ¼ö ÀÖ¾î ȯÀڵ鿡°Ô ÀçÁ¤Àû À庮À» Á¶¼ºÇÏ°í ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÕ´Ï´Ù. ƯÈ÷ ÃÖ±Ù ³Ä¡¼º °£Áú Ä¡·á¿¡ ½ÂÀÎµÈ Ç×°£Áú ¾à¹°(AED)´Â ³ôÀº °¡°ÝÀ» µ¿¹ÝÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ¹ßÀÛ ÅëÁ¦¿¡ È¿°úÀûÀÏ ¼ö ÀÖÁö¸¸, ºñ¿ëÀº ÀÇ·á ½Ã½ºÅÛ°ú ȯÀÚ ¸ðµÎ¿¡°Ô ºÎ´ãÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ °³¹ßµµ»ó±¹À̳ª º¸Çè Àû¿ëÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼ ´õ¿í ±×·¸½À´Ï´Ù.
½ÃÀå ¼ºÀåÀ» ¸·´Â ´Ù¸¥ °úÁ¦´Â ´ÙÀ½°ú °°½À´Ï´Ù.
½ÃÀå ±âȸ :
³Ä¡¼º °£Áú Ä¡·á¸¦ À§ÇÑ ½Å°æÁ¶Àý ÀåÄ¡ÀÇ ±â¼ú ¹ßÀü ½ÃÀå : ½Å°æÁ¶ÀýÀº ¾à¹° ÀúÇ×¼º °£Áú(DRE) °ü¸®¿¡ Çõ½ÅÀûÀÎ Á¢±Ù ¹æ½ÄÀ¸·Î ºÎ»óÇϸç, ÀüÅëÀûÀÎ Ç×¹ßÀÛ ¾à¹°¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚ¿¡°Ô Èñ¸ÁÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ħ½ÀÀû ¹× ºñħ½ÀÀû ½Å°æÁ¶Àý ±â¼úÀÇ ÃÖ±Ù ¹ßÀüÀº ¹ßÀÛ ÅëÁ¦·ÂÀ» Å©°Ô Çâ»ó½Ã۰í ȯÀÚ ¿¹Èĸ¦ °³¼±Çϸç Ä¡·á ¿É¼ÇÀ» È®´ëÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Ä¡·á ȯ°æÀ» È®ÀåÇÏ¿© ½Å°æÁ¶ÀýÀ» ³Ä¡¼º °£Áú °ü¸®ÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±è½ÃÄ×½À´Ï´Ù. Ãֽбâ¼ú°ú °³ÀÎÈ Ä¡·á Á¢±Ù¹ýÀÇ ÅëÇÕÀº ½ÃÀåÀÇ ¿ªµ¿ÀûÀÎ ÁøÈ¿Í ¾à¹° ÀúÇ×¼º °£ÁúÀÇ º¹À⼺À» ÇØ°áÇϱâ À§ÇÑ Çå½ÅÀ» °Á¶ÇÕ´Ï´Ù.
½ÃÀå µ¿Çâ :
°í±Þ ¿µ»ó ±â¼úÀÇ ÅëÇÕÀ» ÅëÇÑ Áø´Ü ¹× Ä¡·á °³¼±: ³Ä¡¼º °£Áú Ä¡·áÀÇ µ¿Çâ´Â °í±Þ ¿µ»ó ±â¼ú, À¯ÀüüÇÐ, AI ±â¹Ý ¼Ö·ç¼ÇÀ» ÅëÇÕÇÏ¿© °íǰÁúÀÇ °³ÀÎÈ µÈ Ä¡·á¸¦ Á¦°øÇÏ´Â ¹æÇâÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀº ¾Ï°ú °°Àº Áúȯ¿¡ ´ëÇÑ ´ÙÂ÷¿øÀû ÀÌÇØ¸¦ Á¦°øÇÔÀ¸·Î½á Áø´Ü ¹× Ä¡·á °èȹÀÇ Á¤È®¼º°ú È¿°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶óµð¿À¹Í½º¿Í AI´Â ÀÇ·á ¿µ»ó¿¡¼ ½ÇÇà °¡´ÉÇÑ ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á Á¾¾ç ÀÌÁú¼º°ú ȯÀÚ Æ¯ÀÌÀû ¿äÀο¡ ´ëÇÑ ±íÀº ÀÌÇØ¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ÀÓ»óÀû ÀÇ»ç°áÁ¤À» Çõ½ÅÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¬¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú »ý¹°¹°¸®ÇÐÀû ¸ðµ¨¸µÀº ½Ç½Ã°£ ºÐ¼®°ú ¸ÂÃãÇü Ä¡·á ½Ã¹Ä·¹À̼ÇÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÀÓ»ó °á°ú¸¦ ´õ¿í °³¼±ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÀüÅëÀûÀÎ ¹æ¹ýº¸´Ù ¿ì¼öÇÑ °á°ú¸¦ Á¦°øÇÏ´Â °íǰÁú ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀåÀÇ ´Ù¸¥ »õ·Î¿î µ¿ÇâÀº ´ÙÀ½°ú °°½À´Ï´Ù.
Á¦Ç°/Çõ½Å Àü·« : º¸°í¼´Â ³Ä¡¼º °£Áú Ä¡·á ºÐ¾ßÀÇ Ãֽбâ¼ú µ¿ÇâÀ» ½ÉÃþ ºÐ¼®ÇÏ¿© Á¶Á÷ÀÌ Çõ½ÅÀ» ÁÖµµÇÏ°í ½ÃÀå ¼ö¿ä¿¡ ¸Â´Â ÃÖ÷´Ü Á¦Ç°À» °³¹ßÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.
¼ºÀå/¸¶ÄÉÆÃ Àü·« : Æ÷°ýÀûÀÎ ½ÃÀå ºÐ¼®°ú ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ½Äº°ÇÔÀ¸·Î½á, º¸°í¼´Â Á¶Á÷ÀÌ Å¸°ÙÆÃµÈ ¸¶ÄÉÆÃ Àü·«À» ¼ö¸³ÇÏ°í ½ÃÀå Á¡À¯À²À» È¿°úÀûÀ¸·Î È®´ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.
°æÀï Àü·« : °æÀï ȯ°æ ºÐ¼®À» ÅëÇØ Á¶Á÷ÀÌ °æÀï»çÀÇ °Á¡°ú ¾àÁ¡À» ÀÌÇØÇÏ°í ½ÃÀå¿¡¼ÀÇ °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇÑ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.
±ÔÁ¦ ¹× Áؼö Àü·« : º¯ÈÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ÂÀÎ ÀýÂ÷, »ê¾÷ °¡À̵å¶óÀο¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ Á¦°øÇÏ¿© Á¶Á÷ÀÌ ±ÔÁ¦ Áؼö ¿ä°ÇÀ» ÃæÁ·ÇÏ°í »õ·Î¿î ³Ä¡¼º °£Áú Ä¡·á ¼Ö·ç¼ÇÀÇ ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.
ÅõÀÚ ¹× »ç¾÷ È®Àå Àü·« : ½ÃÀå µ¿Çâ, ÀÚ±Ý Á¶´Þ ÆÐÅÏ, ÆÄÆ®³Ê½Ê ±âȸ¸¦ ºÐ¼®ÇÏ¿© Á¶Á÷ÀÌ Á¤º¸¿¡ ±â¹ÝÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í »ç¾÷ ¼ºÀå À§ÇÑ ÀáÀçÀû M&A ±âȸ¸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.
ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷°ú °æÀï ±¸µµ
±â¾÷ ÇÁ·ÎÆÄÀÏÀº 1Â÷ Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÀԷ°ú ±â¾÷ Ä¿¹ö¸®Áö, Á¦Ç° Æ÷Æ®Æú¸®¿À ¹× ½ÃÀå ħÅõµµ ºÐ¼®À» ±â¹ÝÀ¸·Î ¼±Á¤µË´Ï´Ù.
³Ä¡¼º °£Áú Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Ä«¸£¹Ù¸¶Á¦ÇÉÀ̳ª Æä´ÏÅäÀΰú °°Àº ÀüÅëÀûÀÎ ¾àÁ¦¿¡¼ ¼¼³ë¹Ù¸ÞÀÌÆ®(Xcopri)³ª Ŭ·Î¹ÙÀá(Onfi)°ú °°Àº ½Å¾à¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Ç× °£Áú ¾à¹°(AED)¸¦ Á¦°øÇÏ´Â ¼¼°èÀÇ ÁÖ¿ä Á¦¾à ±â¾÷À» Æ÷ÇÔÇÕ´Ï´Ù. Àü¹® ±â¾÷Àº Dravet ÁõÈıº°ú Lennox-Gastaut ÁõÈıº°ú °°Àº ÁõÈıºÀ» Æ÷ÇÔÇÏ¿© µå¹°°í ½É°¢ÇÑ °£Áú¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ±Ô ÈÇÕ¹°ÀÇ °³¹ß¿¡ ÀÓÇϰí ÀÖ½À´Ï´Ù.ÀúºÐÀÚ Ä¡·áÁ¦´Â ±Þ¼º ¹ßÀÛ ¹ß»ý½Ã¿¡ º¸´Ù ÁÁÀº °³ÀÔÀ» ½Ç½ÃÇϱâ À§Çؼ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ GABA-A ¼ö¿ëü ¸ðµâ·¹ÀÌÅÍ ¹× ±âŸ Çõ½ÅÀûÀΠâ¾à Ç¥ÀûÀ» °³¹ßÇÏ¿© °£Áú Ä¡·á °³¼±¿¡ ÀÓÇϰí ÀÖ´Â ±â¾÷µµ ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ³Ä¡¼º °£Áú Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Ä¡·á À¯Çüº°, ȯÀÚ À¯Çüº°, ¹ßÀÛ À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
This report can be delivered within 1 working day.
Introduction of Refractory Epilepsy Treatment
Refractory epilepsy treatment utilizes an individual's distinct clinical, molecular, and lifestyle data to inform the diagnosis, treatment, and prevention of cancer, inherited diseases, and other complex conditions. Refractory epilepsy treatment represents a transformative shift in healthcare, moving away from the traditional one-size-fits-all approach to a more tailored and targeted therapeutic strategy. By leveraging advancements in genomics, molecular diagnostics, and data analytics, Refractory epilepsy treatment enables healthcare providers to craft personalized treatment plans based on an individual's genetic, environmental, and lifestyle factors. This approach not only promises to enhance the effectiveness of treatments but also reduces unnecessary trial-and-error, leading to better patient outcomes and reduced healthcare costs. As the field continues to evolve, large-scale population studies and cutting-edge technologies are paving the way for more accurate disease predictions, early diagnoses, and optimized therapeutic interventions.
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2025 - 2035 |
2025 Evaluation | $4,902.4 Million |
2035 Forecast | $9,472.6 Million |
CAGR | 6.71% |
Market Introduction
The global refractory epilepsy treatment market is expected to witness substantial growth, projected to reach $9,472.6 million by 2035. The global refractory epilepsy treatment market is experiencing consistent growth, driven by the increasing prevalence of epilepsy and the limitations of conventional anti-seizure medications, which fail to control seizures in approximately 30-40% of patients. This significant unmet clinical need is transforming the market landscape, spurring demand for advanced treatment options such as neurostimulation therapies (including VNS, RNS, and DBS), surgical interventions, and innovative therapeutics like cannabidiol and next-generation anti-seizure medications. Growth is further supported by rising awareness, enhanced diagnostic capabilities, and broader healthcare access in emerging markets. Nonetheless, barriers such as high treatment costs, complex regulatory requirements, and uneven access to specialized care continue to hinder widespread adoption. As the field moves toward more personalized, device-integrated, and precision-targeted solutions, the refractory epilepsy treatment market stands at the forefront of urgent clinical need and evolving commercial potential.
Refractory epilepsy, also known as drug-resistant epilepsy (DRE), affects approximately 30% of all epilepsy patients, who do not respond adequately to at least two anti-seizure medications (ASMs). This condition represents a high unmet clinical need, driving both pharmaceutical and device innovation. Refractory epilepsy, affects roughly 30% of the global epilepsy population, representing a significant unmet medical need. This subset of patients fails to achieve seizure control despite trials of two or more anti-seizure medications (ASMs), driving demand for innovative therapies. The competitive landscape is diverse and rapidly evolving, spanning pharmaceutical, device, and emerging gene therapy sectors. Traditional ASMs, such as UCB Pharma's brivaracetam and SK Life Science's cenobamate, continue to advance with a focus on improved efficacy and tolerability, exemplified by cenobamate's clinical trials showing notable seizure freedom rates. Meanwhile, neuromodulation devices-like LivaNova's vagus nerve stimulation and NeuroPace's responsive neurostimulation system-offer alternative approaches targeting neural circuits, particularly for patients with focal epilepsy not amenable to surgery.
Additionally, cell and gene therapies, though still in early stages, promise transformative potential for rare genetic epilepsies such as Dravet syndrome, reflecting a shift towards precision medicine. Market growth is supported by regulatory incentives and increasing payer acceptance, particularly as real-world data validate the long-term benefits of these advanced therapies. Overall, the refractory epilepsy treatment landscape resembles a multi-modal transportation system navigating difficult terrain: conventional drugs serve broad populations but with limited efficacy, neuromodulation provides more precise control albeit at higher cost, and emerging genetic therapies hold the promise of a targeted, curative path for select patients.
Industrial Impact
Refractory epilepsy treatment is reshaping the healthcare industry by enabling personalized treatments that significantly improve patient outcomes. For instance, the use of genetic profiling in oncology has led to the development of targeted therapies such as Herceptin for breast cancer, which is specifically designed to treat patients with HER2-positive tumors. In addition to improving individual patient care, Refractory epilepsy treatment is driving innovation across the healthcare ecosystem, particularly in drug discovery and clinical trials. The pharmaceutical industry is leveraging genomics to discover new drug targets, as seen in the development of the breakthrough drug Kymriah, a CAR-T therapy for leukemia, which was developed through the identification of genetic markers specific to the disease. Clinical trials are also becoming more targeted, with companies such as Novartis and Pfizer using genomic data to stratify patient populations and improve trial efficiency. Moreover, the integration of refractory epilepsy treatment into population health management is evident in initiatives such as Geisinger Health System's MyCode Community Health Initiative, which offers genomic sequencing to patients to improve preventive care and early disease detection. This growing application of refractory epilepsy treatment has not only improved individual treatment outcomes but has also helped to optimize healthcare delivery systems, reduce costs, and accelerate the development of new therapies.
Market Segmentation:
Segmentation 1: By Treatment Type
First-Generation Drugs
Second-Generation Drugs
New and Emerging Drugs
Combination Drugs
Resective Surgery Devices
Laser Interstitial Thermal Therapy (LiTT)
Stereotactic EEG
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Electrodes/Leads
Batteries and Pulse Generators
Surgical Tools and Kits
External Accessories
Pharmacological treatment remains the leading segment due to the widespread use of anti-epileptic drugs (AEDs) as the first-line approach for managing refractory epilepsy. The segment holds a market share of 90.60% in 2024 with a CAGR of 6.87% during the forecast period 2025-2035. Continuous advancements in drug formulations, coupled with the increasing availability of next-generation AEDs with improved efficacy and fewer side effects, are expected to drive growth in this segment through 2035.
Segmentation 2: By Patient Type
Based on patient type, the global refractory epilepsy treatment market was led by the paedaitrics segment, which held a 59.6% share in 2024. The paediatric population is projected to dominate the refractory epilepsy treatment market due to a higher prevalence of epilepsy among children compared to adults. Additionally, improved diagnosis rates, a growing aging population, and higher healthcare awareness in adult groups contribute to the rising demand for effective treatment solutions.
Segmentation 3: By Seizure Type
Based on seizure ype, the global refractory epilepsy treatment market was led by the focal segment, which held a 61.4% share in 2024. Focal epilepsy is expected to lead the market as it accounts for a significant proportion of refractory epilepsy cases. Its complex and variable presentation often makes it resistant to standard therapies, driving the need for advanced treatment approaches, including newer pharmacological options and neuromodulation techniques
Segmentation 4: By Distribution Channel
Based on distribution channel, the global refractory epilepsy treatment market was led by the hospital pharmacy segment, which held a 45.7% share in 2024. Hospital pharmacies are anticipated to dominate the distribution channel due to their access to specialized medications and advanced treatment infrastructure. The rising number of hospital-based treatment protocols and the preference for inpatient care in severe cases of refractory epilepsy further support this segment's growth.
Segmentation 5: By Region
The refractory epilepsy treatment market in the North America region is expected to witness a significant growth rate during the forecast period, marked by a high disease burden, advanced healthcare infrastructure, and a strong focus on innovation. The market is expected to witness notable growth over the next five years due to increasing R&D investments, rising patient awareness, and improved diagnostic capabilities. Key developments include the FDA's recent approval of Cenobamate by SK Life Science, which has demonstrated effectiveness in treatment-resistant seizures, and the ongoing late-stage development of promising candidates such as XEN1101 by Xenon Pharmaceuticals. Leading companies are actively pursuing novel mechanisms of action and personalized medicine approaches to improve efficacy and minimize side effects. Additionally, strategic initiatives like expanded patient assistance programs and public-private research collaborations are expected to enhance access and accelerate innovation.
Recent Developments in the Refractory Epilepsy Treatment Market
Demand -Drivers, Challenges, and Opportunities
Market Demand Drivers:
Increasing prevalence of drug-resistant epilepsy and ever expanding pipeline of novel therapeutics: Refractory epilepsy is defined by the International League Against Epilepsy (ILAE) as the failure to achieve sustained seizure freedom after adequate trials of at least two appropriately chosen and tolerated anti-epileptic drugs (AEDs). Individuals with this form of epilepsy face greater health complications, increased risk of injury or sudden death (SUDEP), and significantly reduced quality of life. The rising prevalence of this epilepsy further amplifies the burden on healthcare systems.
According to UChicago Medicine, an estimated 65 million people worldwide live with epilepsy, and among those, 30-40 percent, roughly 20-26 million individuals, have drug-resistant or medically refractory epilepsy, meaning they fail to achieve sustained seizure control despite trials of two or more appropriate antiseizure medications. In the U.S. alone, there are over 2 million people with refractory epilepsy, and in India, where 10-12 million people have epilepsy, approximately 30-40 percent (3-4 million) are estimated to be drug-resistant, underscoring a substantial and growing treatment gap worldwide.
The increasing number of patients diagnosed with medication-refractory epilepsy across Africa has emerged as a key driver for the regional and global refractory epilepsy treatment market. "Surgery for Medication Refractory Epilepsy in Africa: A Review of Seizure Freedom Outcomes", published in 2024, systematically reviews epilepsy surgery programs across Africa. Analyzing eight studies representing seven unique patient cohorts, the review found that 60-100% of patients achieved seizure freedom within a year post-surgery, alongside improvements in quality of life and reduced depression severity. These outcomes are comparable to those reported in higher-income regions, demonstrating the feasibility and effectiveness of establishing refractory epilepsy surgery programs in Africa. Given here is a graphical representation of the number of patients undergoing various surgical procedures for medication-refractory epilepsy in Africa. CAH, corticoamygdalohippocampectomy; SAH, selective amygdalohippocampectomy.
Some of the other driving factors include:
Note: All of the above factors will be evaluated in detail in the report.
Market Challenges:
Financial Constraints on Patient Access: The financial constraints on patient access are a significant challenge for the refractory epilepsy treatment market, particularly because many patients with refractory epilepsy often require a combination of therapies, including newer medications, advanced surgical options, or devices like Vagus Nerve Stimulation (VNS) or Responsive Neurostimulation (RNS). These treatments can be prohibitively expensive, creating financial barriers for patients and limiting market growth. AEDs, especially those approved in recent years for refractory epilepsy, often come with high price tags. Although they may offer effective seizure control, their cost can be a burden for both healthcare systems and patients, especially in developing countries or where insurance coverage is limited.
Some of the other factors challenging the market growth include:
Note: All of the above factors will be evaluated in detail in the report.
Market Opportunities:
Advances in Neuromodulation Devices in Refractory Epilepsy Treatment Market: Neuromodulation has emerged as a transformative approach for managing drug-resistant epilepsy (DRE), offering hope to patients unresponsive to conventional antiseizure medications. Recent advancements in both invasive and non-invasive neuromodulation technologies have significantly enhanced seizure control, improved patient outcomes, and expanded therapeutic options. These advancements not only enhance patient outcomes but also expand the therapeutic landscape, positioning neuromodulation as a central component in the management of refractory epilepsy. The integration of cutting-edge technologies and personalized treatment approaches underscores the market's dynamic evolution and its commitment to addressing the complexities of drug-resistant epilepsy.
Some of the other factors creating an opportunity for market growth include:
Note: All of the above factors will be evaluated in detail in the report.
Market Trends:
Integrating Advanced Imaging for Enhanced Diagnostics and Treatment: The trend in Refractory Epilepsy Treatment is shifting toward delivering high-quality, personalized care through the integration of advanced imaging technologies, genomics, and AI-driven solutions. This approach enhances the accuracy and effectiveness of diagnoses and treatment plans by offering a multi-dimensional understanding of diseases such as cancer. Radiomics and AI are transforming clinical decision-making by providing actionable insights from medical images, enabling a deeper understanding of tumor heterogeneity and patient-specific factors. Additionally, cloud-based platforms and biophysical modeling are allowing for real-time analysis and personalized treatment simulations, further improving clinical outcomes. As these technologies evolve, the demand for high-quality, tailored therapies is expected to rise, offering better results than traditional methods.
Some of the other emerging trends in the market include:
Note: All of the above trends will be evaluated in detail in the report.
How can this report add value to an organization?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in refractory epilepsy treatment, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Refractory Epilepsy Treatment solutions.
Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in Refractory Epilepsy Treatment, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.
Key players in the refractory epilepsy treatment market include major global pharmaceutical companies offer a range of antiepileptic drugs (AEDs), including traditional drugs like carbamazepine and phenytoin, as well as newer medications such as cenobamate (Xcopri) and clobazam (Onfi). Specialty companies focus on rare and severe forms of epilepsy, including syndromes like Dravet syndrome and Lennox-Gastaut syndrome. Biotech companies are working on developing novel compounds that target ion channels involved in seizure activity. Small molecule therapies are being developed to offer better intervention during acute seizure events. Research into epilepsy syndromes is yielding promising results for disorders with unique sensitivities to light and other triggers. Other companies are working on GABA-A receptor modulators and other innovative drug targets to improve epilepsy treatment. Companies with a focus on refractory conditions also work on therapies targeting status epilepticus and related complications.
Some prominent names established in this market are:
Scope and Definition